Abstract:BACKGROUND: Although Mex3 RNA-binding family member A (Mex3a) has demonstrated an important role in multiple cancers, its role and regulatory mechanism in CRC is unclear. In this study, we aimed to investigate the role and clinical significance of Mex3a in CRC and to explore its underlying mechanism.METHODS: Western blotting and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to detect the expression levels of genes. 5-Ethynyl-2'-deoxyuridine (EDU) and transwell assays were utilized to examine CRC cell proliferation and metastatic ability. The R software was used to do hierarchical clustering analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Overexpression and rescue experiments which included U0126, a specific mitogen activated protein kinase kinase/extracellular regulated protein kinase (MEK/ERK) inhibitor, and PX-478, a hypoxia-inducible factor 1 subunit alpha (HIF-1α) inhibitor, were used to study the molecular mechanisms of Mex3a in CRC cells. Co-immunoprecipitation (Co-IP) assay was performed to detect the interaction between two proteins. Bioinformatics analysis including available public database and Starbase software (starbase.sysu.edu.cn) were used to evaluate the expression and prognostic significance of genes. TargetScan (www.targetscan.org) and the miRDB (mirdb.org) website were used to predict the combination site between microRNA and target mRNA. BALB/c nude mice were used to study the function of Mex3a and hsa-miR-6887-3p in vivo.RESULTS: Clinicopathological and immunohistochemical (IHC) studies of 101 CRC tissues and 79 normal tissues demonstrated that Mex3a was a significant prognostic factor for overall survival (OS) in CRC patients. Mex3a knockdown substantially inhibited the migration, invasion, and proliferation of CRC cells. Transcriptome analysis and mechanism verification showed that Mex3a regulated the RAP1 GTPase activating protein (RAP1GAP)/MEK/ERK/HIF-1α pathway. Furthermore, RAP1GAP was identified to interact with Mex3a in Co-IP experiments. Bioinformatics and dual-luciferase reporter experiments revealed that hsa-miR-6887-3p could bind to the 3'-untranslated regions (3'-UTR) of the Mex3a mRNA. hsa-miR-6887-3p downregulated Mex3a expression and inhibited the tumorigenesis of CRC both in vitro and in vivo.CONCLUSIONS: Our study demonstrated that the hsa-miR-6887-3p/Mex3a/RAP1GAP signaling axis was a key regulator of CRC and Mex3a has the potential to be a new diagnostic marker and treatment target for CRC.

The RNA‐binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma

RNA-binding Protein MEX3A Controls G1/S Transition Via Regulating the RB/E2F Pathway in Clear Cell Renal Cell Carcinoma

The RNA Binding Protein MEX3A Promotes Tumor Progression of Breast Cancer by Post-Transcriptional Regulation of IGFBP4

CircNEIL3 Regulatory Loop Promotes Pancreatic Ductal Adenocarcinoma Progression Via Mirna Sponging and A-to-I RNA-editing

Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa‐miR‐6887‐3p

RNA-Binding Protein MEX3A Interacting with DVL3 Stabilizes Wnt/β-Catenin Signaling in Endometrial Carcinoma.

Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy

MEX3A Knockdown Inhibits the Development of Pancreatic Ductal Adenocarcinoma

Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma

Clinical Characteristics and Prognostic Value of MEX3A Mrna in Liver Cancer

MEX3A Determines in Vivo Hepatocellular Carcinoma Progression and Induces Resistance to Sorafenib in a Hippo-dependent Way

PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.

RNA-binding protein MEX3D promotes cervical carcinoma tumorigenesis by destabilizing TSC22D1 mRNA

METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation

METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity

Knockdown Of Hmex-3a By Small Rna Interference Suppresses Cell Proliferation And Migration In Human Gastric Cancer Cells

MicroRNA-33a-mediated Downregulation of Pim-3 Kinase Expression Renders Human Pancreatic Cancer Cells Sensitivity to Gemcitabine

Meg3 is A Prognostic Factor for Crc and Promotes Chemosensitivity by Enhancing Oxaliplatin-Induced Cell Apoptosis

Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.

MEX3A promotes triple negative breast cancer proliferation and migration via the PI3K/AKT signaling pathway

An M5c Methylation Regulator-Associated Signature Predicts Prognosis and Therapy Response in Pancreatic Cancer